Navigation Links
University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients

New data presented at annual American Transplant Congress in Toronto

MIAMI, June 2 /PRNewswire/ -- Manuel R. Carreno, MD, and colleagues in the Departments of Surgery and Pathology at the University of Miami - Lawrence Miller School of Medicine have corroborated the value of monitoring cell- mediated immunity (CMI) post transplant in recipients of kidney transplants using a regular laboratory assay of cell function (ImmuKnow(R)/Cylex). Their paper, entitled "Immune monitoring with Cylex ImmuKnow(R) in the management of post kidney transplant recipients," will be presented on June 2 at the annual meeting of the American Transplant Congress in Toronto, Canada.

"The production of cyclic adenosine monophosphate (cAMP) by mitogen-stimulated peripheral CD4+ T-cells using the ImmuKnow assay has previously be shown to have utility in the management of several forms of organ transplantation," stated Dr. Carreno, "In this study, we wanted to learn whether the ImmuKnow test data correlated with data from other tests and clinical findings in patients undergoing kidney transplantation." Dr Carreno is the Assistant Director of Flow Cytometry and Cell Analysis in the University of Miami Transplant Laboratories.

Patients undergoing kidney transplantation were immunosuppressed post-transplant and their immunosuppressed state was maintained with a combination of tacrolimus (Prograf(R)) and low-dose steroids. A total of 2,096 specimens were drawn from 339 transplant patients, and additional samples were provided by normal controls. Levels of CMI, as measured in terms of levels of ATP, were measured using the ImmuKnow assay and categorized according to the tests labeling: "low" (<225 ng ATP/mL), "moderate" (225-525 ng ATP /mL) and "strong" (>525 ng ATP /mL).

Several patterns of ATP level over time were noted in the patients and in the normal controls, as follows:

-- The mean level of CMI for blood samples from normal controls (n = 20)

was 432 +/- 150 ng ATP/mL (generally well within the "moderate" range).

-- Blood samples from patients prior to kidney transplant (n = 91) had a

mean CMI level of 342.1 +/- 155 ng ATP/mL, which was lower than that of

the normal controls but significantly higher (p < 0.005) than the

levels post transplant (see below).

-- Blood samples taken from patients within four time periods post

transplant had the following mean CMI levels

-- 1 to 30 days (Month 1): mean CMI = 203.7 +/- 171 ng ATP/mL

-- 31 to 365 days (Months 2 to 12) mean CMI = 249.1 +/- 162 ng ATP/mL

-- 366 to 730 days (Year 2) mean CMI = 278.3 +/- 147 ng ATP/mL

-- 731 to 1,090 days (Year 3) mean CMI = 263.5 +/- 136 ng ATP/mL

Patients whose pre-transplant CMI level tested in the "strong" ImmuKnow range (n = 10), and whose CMI level remained in the "strong" range post-transplant, showed no evidence of organ rejection. Several patients showed evidence of cellular (n = 8) or humoral (n = 2) rejection while under monitoring. The patients demonstrating cellular rejection all had increases in CMI > 200 ng ATP/mL, with rapid returns toward the mean post-transplant CMI level after good immune function was restored. The two patients demonstrating humoral rejections showed no changes in CMI. Finally, of the 23 patients who contracted infections, 21 (91 percent) demonstrated a drop in CMI level of > 150 ng ATP/mL.

"We believe that serial monitoring of blood samples from kidney transplant patients pre- and post-transplant is now an important aid in the clinical management of these patients," said Phillip Ruiz. MD, PhD, professor of surgery and pathology and head of the Division of Immunopathology. "CMI levels vary significantly, even among stable transplant patients. However, by establishing pre-surgical and post-surgical baseline levels, and monitoring the patients on a regular basis over time, we are able to watch for sudden, significant changes in the patients' CMI levels, which are predictive of either infection or onset of cellular transplant rejection."

The clinical research team further noted that among 29 patients with persistently low CMI levels (< 100 ng ATP/mL) they observed none of the major consequences reported by other investigators and that low absolute CD4+ T-cell levels did not impede the potential for "strong" ImmuKnow response levels.

About ImmuKnow(R)

ImmuKnow is an immune cell function assay that can detect cell-mediated immunity (CMI) in adult patient populations undergoing immunosuppressive therapy for organ transplantation by measuring the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation.

The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of ImmuKnow assays should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient. The use of the ImmuKnow assay as described in this study has not been approved or cleared by the FDA. The company may use data from this or similar studies to support a future FDA marketing application for a similar indication.

About Cylex, Incorporated

Cylex(TM) is a privately held global life sciences company and a leader in the development and manufacture of research and in vitro diagnostic products intended to assist in the assessment of immune function. Cylex is the first and only company to offer a patent-protected in vitro diagnostic assay (ImmuKnow) used in the detection of cell-mediated immune function in immune-suppressed organ transplant patient populations. The ImmuKnow assay is increasingly being adopted for use by organ transplant centers throughout the USA and in other countries around the world. The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure immune cell function for the development of new diagnostics, biomarkers, and companion assays. The company is based in Columbia, MD.

SOURCE Cylex, Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
2. Boston University Biomedical Engineers Find Chink in Bacterias Armor
3. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
4. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
5. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
7. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
8. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
9. Nobel Laureate Dr. Gunter Blobel to Speak at Florida Atlantic University
10. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
11. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
Post Your Comments:
(Date:10/9/2015)...  Eli Lilly and Company (NYSE: LLY ) ... rights to Locemia,s intranasal glucagon, a potential treatment for ... Intranasal glucagon, which is currently in Phase III clinical ... for severe hypoglycemia. --> ... nasal powder formulation that is delivered in an emergency ...
(Date:10/9/2015)... CHAPEL HILL, N.C. , Oct. 9, 2015 ... Pharmaceutical or Medical Device environments, corporate communications is ... external communications, corporations and professionals must continuously adjust ... the effectiveness of these adjustments is difficult, but ... to today,s communication options. ...
(Date:10/9/2015)... , Oct. 9, 2015 Regulatory affairs groups ... --> --> These specialized groups ... the plethora of global regulations pertaining to the development and ... role, regulatory groups largely rely on their own internal effectiveness ... --> --> ...
Breaking Medicine Technology:
... Minn., May 4, 2011 American Medical Systems® ... devices and therapies for male and female pelvic health, ... Ministry of Health, Labor and Welfare (MHLW) to market ... the treatment of Benign Prostatic Hyperplasia (BPH), or enlarged ...
... 4, 2011 The most recent release of Via ... decision support for advance care planning to encourage early ... treatment intent and likely outcomes. Recent ... effect that attention to planning end of life care ...
Cached Medicine Technology:
(Date:10/10/2015)... Clarkston, Metamora, Michigan (PRWEB) , ... October 10, 2015 , ... ... Up to 10% of cancer patients have an inherited gene mutation. Fortunately, knowing family ... stage. Women with certain genetic mutations have:, · up to 44% lifetime risk of ...
(Date:10/10/2015)... ... October 10, 2015 , ... Adenomyosis is ... uterus, the endometrium, grows inside the muscle layer of the uterus. It's a ... of adenomyosis are similar to the symptoms of endometriosis and may include pelvic ...
(Date:10/10/2015)... Chicago, IL (PRWEB) , ... October 10, 2015 , ... With the winter season coming ... manufacturer of low-watt heaters, Cozy Products is familiar with the problem and discusses ... a few degrees to the inside of the chicken coop in the winter, utilize a ...
(Date:10/10/2015)... ... ... have to walk with crutches for the rest of my life," said an inventor from ... that would give me more independence and freedom would be amazing. This inspired me to ... developed the STRAP IN to enable an individual to walk with crutches without having to ...
(Date:10/10/2015)... ... , ... The sixth annual cost of cybercrime study the Ponemon Institute released ... companies. The New York Times broke down some of those numbers in this ... among the companies surveyed, it only proves that regular threat assessments, penetration testing and ...
Breaking Medicine News(10 mins):
... Sales and Marketing Veteran to Drive International Retail Expansion, ... Group and New WrinkleFree Brand Line ExtensionIRVINE, Calif., Jan. ... developer and distributor of medically developed and efficacy-based skin ... mass market retail locations throughout the U.S., announced today ...
... The following statement can be attributed to Michael ... has consistently said two things: We are not ... But we have urged public policy makers to ... merger without conditions, because without conditions the merger ...
... (Nasdaq: OMCL ), a leading provider of system solutions to acute healthcare ... quarter 2008 financial results. , What: Omnicell ... webcast, When: January ... Lipps, chairman, president and chief executive officer, ...
... Maine, Jan. 21 IDEXX Laboratories, Inc. (Nasdaq: ... quarter and full-year financial results for Friday, January 30, at ... conference call beginning at 9:00 a.m. (eastern) on that day. ... through a link on the IDEXX Web site, ...
... can lead to failure, , , WEDNESDAY, Jan. 21 (HealthDay ... a common cause of kidney transplant failure may help ... polyomavirus nephropathy, which affects about 9 percent of kidney ... adults but can cause serious problems for people with ...
... CAMBRIDGE, Mass. -- Schizophrenia may blur the boundary between ... that is involved in self-reflection, and thus causing an ... brain imaging study has found. , The traditional ... and emotions that characterize the disease are caused by ...
Cached Medicine News:
Disposable tracheostomy care tray....
Disposable tracheostomy care tray....
... the Right Solution For Your Tracheostomy Care ... care tray features the latest components for ... infection control task. Designed by clinicians, these ... of each patient and caregiver. All of ...
... For Your Tracheostomy Care Needs, ,Each ... the latest components for efficient and convenient ... Designed by clinicians, these latex-free trays provide ... and caregiver. All of our trays also ...
Medicine Products: